Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
